Fluorescence of ocular surface in a Covid-19 patient after Favipiravir treatment: a case report

Background Favipiravir is used in treatment of Covid-19 patients. We aimed to share of ocular surface fluorescence in a patient after Favipiravir treatment in this case report. Case presentation A 20-year-old male patient declared no known systemic disease prior to Covid-19. He applied to us with blurry vision and blue light reflection after Covid-19 treatment with Favipiravir. We observed bilateral fluorescence on his eyes and fluorescence of his nails. Biomicroscopic examination was insignificant. Conclusion We investigated the fluorescence of favipiravir tablets under ultraviolet light. Drug demonstrated fluorescence. We recorded the favipiravir fluorescence in-vitro. This appears to be a strong evidence in terms of the linkage between the fluorescence of the ocular surface and favipiravir.

Automated summary

Background: Favipiravir is used to treat Covid-19 patients. We reported a case of ocular surface fluorescence in a patient after Favipiravir treatment. The patient, a 20-year-old male, presented with blurry vision and blue light reflection following Favipiravir treatment for Covid-19. Fluorescence was observed in both eyes and nails, with insignificant findings on biomicroscopic examination. Investigation showed that Favipiravir tablets exhibit fluorescence under ultraviolet light, providing strong evidence of a link between ocular surface fluorescence and Favipiravir.